Bacterial Infections Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Oral QPX2015 in Healthy Adult Subjects
Verified date | May 2019 |
Source | Qpex Biopharma, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
QPX2015 (beta-lactam antibiotic) is being studied at higher than approved doses to combine with a new beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.
Status | Completed |
Enrollment | 40 |
Est. completion date | October 6, 2019 |
Est. primary completion date | October 6, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Healthy adult males and/or females of non-child bearing potential, 18 to 55 years of age (inclusive). 2. Body mass index (BMI) = 18.5 and = 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive). 3. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, electrocardiograms [ECGs], physical examination) as assessed by the PI. 4. Voluntarily consent to participate in the study. 5. If male, agree to be sexually abstinent or agree to use two approved methods of contraception when engaging in sexual activity from study check-in through completion of the end-of-study. Subjects must agree to use two approved methods of contraception for 30 days following the last administration of the study drug, and to not donate sperm during this same period of time. In the event that the sexual partner is surgically sterile, contraception is not necessary. 6. Females of non-childbearing potential with serum FSH levels = 40 mIU/mL are either postmenopausal (defined as 12 months spontaneous amenorrhea) or have undergone sterilization procedures at least 6 months prior to dosing. Exclusion Criteria: 1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease. 2. Positive urine drug/alcohol testing at screening or check-in (Day -1). 3. Positive testing for HIV, hepatitis B or C 4. History or presence of alcoholism or drug abuse within last 2 years 5. Use of more than 5 packs/week of tobacco/nicotine-containing product within last 6 months prior dosing. 6. Use of any prescription medication (with the exception of hormonal contraceptives or hormone replacement therapy for females) within 14 days prior to dosing. 7. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing. 8. Use of antacids, H2 receptor blockers or proton pump inhibitors 3 days prior to dosing. 9. History of any hypersensitivity or allergic reaction to cephalosporins, penicillins, carbapenems, or monobactams). 10. Participation in another investigational clinical trial within 30 days prior to Dosing or within 5 half-lives of the previous investigational drug, whichever is longer. 11. Females who are pregnant or lactating. 12. QTcF interval >450 msec, or history of prolonged QT syndrome at screening or check-in 13. Calculated creatinine clearance less than 80 mL/min (Cockcroft-Gault method) at screening or check-in. 14. Subjects who have any clinically significant abnormalities on laboratory values: White blood cell count < 3,000/mm3, hemoglobin < 11g/dL or Absolute neutrophil count < 1,200/mm3 or platelet count < 120,000/mm3. 15. Liver function abnormalities defined by an elevation in bilirubin, AST or ALT 1.5 x ULN of the normal range for subjects based on age and sex. |
Country | Name | City | State |
---|---|---|---|
Australia | CMAX | Adelaide | South Australia |
Lead Sponsor | Collaborator |
---|---|
Qpex Biopharma, Inc. | Biomedical Advanced Research and Development Authority |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment -Emergent Adverse events by subject and by cohort | Number of patients with Treatment-Emergent AEs by treatment arm, severity and relationship to treatment | Study Day 1 to 13 | |
Primary | Number of patients with changes from baseline in safety parameters | Number of patients with changes in safety parameters before and after dosing by subject and treatment arm | Study Day 1 to 13 | |
Primary | Peak plasma Concentration measurements by subject and by cohort (Cmax) | Comparison will be performed between the cohorts for Cmax. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed. | Study Day 1 to 13 | |
Primary | Time concentration data measurements by subject and by cohort (Tmax) | Comparison will be performed between the cohorts for Tmax. | Study Day 1 to 13 | |
Primary | Area under the plasma concentration versus time curve (AUC) between cohorts | Comparison will be performed between the cohorts for AUC. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed. | Study Day 1 to 13 | |
Primary | Urine PK amount excreted by subject and by cohort | Urine PK parameters such as amount excreted will be calculated from urinary excretion data | Study Day 1 to 13 | |
Primary | Urine PK % dose excreted by subject and by cohort | Urine PK parameters such as amount of % dose excreted will be calculated from urinary excretion data | Study Day 1 to 13 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |